In 2023, Professor Ye Liling’s team conducted a series of tumor transplantation and lymph node excision experiments, which clarified that PD-1/PD-L1 ICB therapy primarily mobilizes TDLN-TTSM (6). This evidence concerns the gene CD274 and neoplasm.